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Natural small compounds comprise most cellular
molecules and bind proteins as substrates, prod-
ucts, cofactors, and ligands. However, a large-scale
investigation of in vivo protein-small metabolite
interactions has not been performed. We developed
a mass spectrometry assay for the large-scale iden-
tification of in vivo protein-hydrophobic small metab-
olite interactions in yeast and analyzed compounds
that bind ergosterol biosynthetic proteins and
protein kinases. Many of these proteins bind small
metabolites; a few interactions were previously
known, but the vast majority are new. Importantly,
many key regulatory proteins such as protein kinases
bind metabolites. Ergosterol was found to bindmany
proteins and may function as a general regulator. It is
required for the activity of Ypk1, a mammalian AKT/
SGK kinase homolog. Our study defines potential
key regulatory steps in lipid biosynthetic pathways
and suggests that small metabolites may play
a more general role as regulators of protein activity
and function than previously appreciated.
INTRODUCTION
During the past decade, considerable effort has been devoted to
analyzing biological networks, particularly protein-protein,
expression, transcription factor binding, and even protein
phosphorylation networks (reviewed in Snyder and Gallagher,
2009). These studies have provided a wealth of information for
understanding protein function, which components work
together, and the basic principles of regulatory network organi-
zation.
In total numbers, small metabolites comprise the vast majority
of cellular components, and like proteins, they are present in
a broad range of cellular concentrations and participate ina wide variety of biochemical and regulatory functions. They
serve as metabolic components, cofactors for enzymes, forms
of energy for biochemical reactions, and regulators of protein
function (Fo¨rster et al., 2003). As regulators of protein function,
metabolites can act globally to control many proteins or
specifically target a limited number of proteins. Examples of
the wide variety of small metabolite-protein associations include
the binding of galactose to a sensor protein (Yano and Fuka-
sawa, 1997), steroid hormones to transcription factors (Evans,
1988), and second messengers, including phospholipids, cyclic
nucleotides, and arachidonic acids to specific cellular targets. In
spite of their importance in mediating protein function and
regulation, systematic approaches for analyzing in vivo interac-
tions have not been performed. Such information is expected
to be valuable not only for elucidating the biochemical activities
and regulation of individual proteins, but also for assembling and
understanding regulatory networks and connections between
biological pathways. Furthermore, because metabolite levels
can be adjusted by dietary intake of nutrients, understanding
the regulation of cellular processes by metabolites has potential
therapeutic value in correcting defects in biochemical pathways.
Saccharomyces cerevisiae has served as an important model
organism for many large-scale studies, including analysis of
protein-protein interactions, phenotypes, genetic interactions,
protein localization, gene expression, and transcription factor
binding (reviewed in Horak and Snyder, 2002; Snyder and
Gallagher, 2009). To date, more than 682 metabolic compounds
have been identified in yeast (Fo¨rster et al., 2003), and many are
known to be hydrophobic; 52% have a logP greater than meth-
anol (Figure S1A). Many models of yeast metabolism have been
generated and are capable of predicting key regulatory meta-
bolic steps (Cascante and Marin, 2008; Herrga˚rd et al., 2008).
Several previous studies have analyzed small molecules and
small molecule-protein interactions in yeast. Metabolites have
been profiled from yeast extracts using mass spectrometry
(Allen et al., 2003), and limited studies to identify metabolites
that bind proteins have been performed (Lee et al., 2007).
Protein and small molecule microarrays have been used to
discover several in vitro interactions (Beloqui et al., 2009;Cell 143, 639–650, November 12, 2010 ª2010 Elsevier Inc. 639
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Figure 1. Flowchart for the Identification of Small Metabolites Bound to Proteins
Molecules bound to a strain expressing a protein of interest relative to a control stain are identified using the scheme presented. See also Figure S1 and Table S1.Kuruvilla et al., 2002; Morozov et al., 2003; Zhu et al., 2001).
Assays to examine small molecule-protein interactions have
been developed (Maynard et al., 2009; Tagore et al., 2008);
however, a systematic effort to identify the small metabolites
that bind to large numbers of proteins in vivo has not been
performed. Thus, the number and types of proteins that bind
small molecules in the cell are not known. Such information is
expected to both help inform potential regulatory interactions
and elucidate the function and regulation of proteins and
pathways.
Here, we present a systematic large-scale investigation of the
endogenous protein-metabolite interactome in yeast. We
focused on the interaction of hydrophobic metabolites with
components of the ergosterol biosynthesis pathway and protein
kinases. Ergosterol biosynthetic enzymes were studied because
we expected that these might bind hydrophobic metabolites,
and protein kinases were chosen because of their importance
in global regulation of protein function. We found that a large
number of proteins bound to hydrophobic metabolites and
described many new interactions. Further analysis has revealed
that the yeast sterol, ergosterol, binds to many protein kinases,
often with 1:1 stoichiometry, and is important for the activity of
a highly conserved kinase, Ypk1, a member of the AKT/SGK
family, and for the protein levels of Ssk22, a MAPKKK involved
in osmotic responses. Ergosterol is the major sterol in yeast,
and analogous to cholesterol in mammals, it is an abundant
component of plasma membranes. Overall, our results
demonstrate that a variety of small metabolite-protein interac-
tions occur in eukaryotes and suggest an extensive role in the
global regulation of protein activities.640 Cell 143, 639–650, November 12, 2010 ª2010 Elsevier Inc.RESULTS
A Large-Scale Assay to Identify Hydrophobic
Compounds Associated with Proteins: Application
to Ergosterol Biosynthetic Enzymes
We developed a sensitive and scalable method to systematically
identify small metabolites bound to proteins using affinity protein
purification and mass spectrometry (Figure 1). In brief, proteins
tagged with an IgG-binding protein domain (Gelperin et al.,
2005) were isolated from lysates using magnetic beads. After
washing, the small metabolites were then extracted in methanol
and analyzed using a reverse-phase C18 column-equipped ultra
performance liquid chromatography (UPLC) column coupled to
a quadrupole time-of-flight (Q-TOF) mass spectrometer. As a
negative control, parallel experiments were performed using
a yeast strain lacking the fusion protein (Y258). The metabolites
significantly enriched in the presence of the fusion relative to the
control strains andmethanol solvent were identified.We focused
on hydrophobic molecules because they are less likely to be
removed from proteins during washes and can readily be
detected by atmospheric pressure chemical ionization (APCI).
The resultant mass spectra are comprised mostly of the proton-
ated precursor ions ([M+H]+), which readily allow small metabo-
lite identification. The mass spectrometry assay was first
developed and standardized using 12 diverse compounds,
including lipid-soluble vitamins from A, D, E, and K families,
and two sterols (ergosterol and lanosterol), which allowed
us to optimize the sensitive detection (200 femtomole in a
mixture in profile scan mode) and separation of each of these
compounds (Figure S1B). We also found that this method
detected more than 340 features in a methanol extract of yeast
cells (an LC profile and list of peaks enriched in the extract rela-
tive to the solvent are in Figure S1C and Table S1), indicating that
its scope is sufficiently broad to cover at least hundreds of
metabolites in a single experiment.
We first established the profiling assay using a group of 21
enzymes involved in ergosterol biosynthesis (Parks and Casey,
1995), whose known substrates and products, most of which
are nonpolar hydrophobic molecules, are readily detectable by
LC-APCI-Q-TOF (Figure 2A). The assays for the Erg proteins
were performed using two to three separate protein preparations
(biological replicates), each containing 0.5–5 picomoles of
protein; for each sample preparation, four to six technical
replicates were analyzed in parallel. The mass spectra data
were analyzed in MarkerLynx or XCMS to identify molecules
based on retention times and accurate molecular mass (see
Experimental Procedures and Figure S1D for details). Because
the background for the peak regions is very low, the correspon-
dence between both technical and biological replicates was
extremely high (mean of relative standard deviation = 7.5% ±
4% for three technical replicates; for biological replicates, see
next section). We therefore used a stringent threshold for calling
positive signals. Finally, protein purity was examined using SDS-
gel electrophoresis after metabolite extraction. In general,
a single ormajor band of the expected size is present in the strain
expressing the fusions relative to the negative control, although
14% of preparations contained more than one band indicative of
either associated proteins or degradation products (Figure S2A
and Figure S3A).
Analysis of the liquid chromatography-mass spectrometry
(LC-MS) results revealed that 16 of the 21 purified Erg proteins
associated with small metabolites (Table 1). One example shown
in Figure 2 contains several compounds associated with Erg6
that eluted from the LC column at retention time 10.84 min
(Figure 2B); this peak contained three mass peaks, which were
significantly lower (t test p value < 0.01, >10-fold signal/control)
in the Y258 yeast control or methanol solvent (Figure 2C). These
three peaks were identified as episterol (381.353 atomic mass
unit [amu]), dimethylzymosterol (395.368 amu), and lanosterol
(409.384 amu), respectively, by elemental composition analysis
and hydrophobicity matching in retention time with known
chemicals (see Figure S1B). Nine other proteins also bound small
metabolites related to ergosterol biosynthesis. A large number of
Erg and other proteins analyzed in this study that were just as
abundant in the protein preparations as the metabolite-binding
protein did not bind any metabolites (Figure S3D). For each of
the 10 proteins that bound ergosterol-related metabolites,
a specific set of associating molecules were observed, and
similarly, each metabolite had a distinct profile. For example,
(S)-2,3-epoxysqualene and 5a-cholesta-8,24-dien-3-one spe-
cifically associated only with Erg1 (Figure 2D), whereas lano-
sterol, ergosterol, and episterol consistently copurified with 5,
5, and 3 Erg proteins, respectively, above the control (Table 1).
One Erg protein was found to bind known substrate (e.g.,
Erg3 bound episterol), and three other Erg proteins bound known
products (e.g., [S]-2,3-epoxysqualene for Erg1), suggesting that
these substrates and products are tightly associated with their
metabolizing/biosynthetic enzymes.Importantly, the majority of metabolite-protein interactions
detected in our assay were new (e.g., dimethylzymosterol for
Erg6) (Table 1). Of particular interest were lanosterol and ergos-
terol, which each bound five Erg proteins. Ergosterol bound its
natural synthesizing enzyme Erg4 and four other enzymes that
control the last five steps in ergosterol biosynthesis, starting
from zymosterol, suggesting a multistep feedback regulatory
mechanism (Figure S2B and Table 1). Ergosterol was not
detected with the known ergosterol-regulated enzyme Hmg1,
probably due to a low level of protein in the protein preparation
(Figure S2A). Although low levels of protein may be an issue in
several instances, it is unlikely to be a major problem overall,
as the distribution of protein levels of the 37 metabolite-binding
proteins identified in our entire study (Erg proteins and protein
kinases) is similar to the distribution of the level of the majority
of the 124 proteins analyzed (Figure S3D). Lanosterol also bound
five enzymes; these enzymes are located at different points in the
biosynthetic pathway. Of interest, unlike other erg mutant
strains, yeast lacking Erg7, the enzyme that produces lanosterol,
fails to grow in the absence of lanosterol (Karst and Lacroute,
1977), suggesting a major role for this lipid in yeast that might
include modulation of protein function. Overall, these results
raise the possibility that, in addition to the known inhibitory regu-
lation of Hmg1 by ergosterol and of Erg13 by acetoacetyl-CoA
(Parks and Casey, 1995), many steps in the ergosterol biosyn-
thesis pathway may be regulated by biosynthetic products of
the pathway (Figure 2A).
New Metabolites Were Discovered
to Bind Yeast Erg Proteins
In addition to well-characterized sterols and other lipids that
bound Erg proteins was an unexpected metabolite, pentapor-
phyrin I. Pentaporphyrin is a heme-related intermediate that
may bind noncovalently to proteins due to the lack of peripheral
methyl groups. It was detected in 7 of 21 Erg enzymes and was
identified using a known standard (Figures 2E and 2F and
Table 1). It is not clear whether this metabolite is ‘‘free’’ porphyrin
or is derived from a bound form after loss of the central coordi-
nated metal ion during LC-MS detection. Nevertheless,
measurements of the binding affinity and stoichiometry revealed
dissociation constants (Kd) of 8–34 mM and pentaporphyrin:pro-
tein stoichiometries of1:1 (for Idi1 and Erg6) to2:1 (for Erg27)
(Figure 2G). The discovery that pentaporphyrin is associated
with several ergosterol biosynthetic components may explain
the observation that elimination of heme synthesis results in
ergosterol auxotrophy (Parks and Casey, 1995) and suggests
that pentaporphyrin-Erg protein interactions are important for
protein function. Thus, our systematic analyses of small-protein
interactions reveal new interactions important for protein
function and further help to explain phenotypes for yeast strains
lacking these different proteins.
Large-Scale Analysis of Hydrophobic Small Metabolites
Bound to Yeast Protein Kinases
Protein kinases control cellular processes and regulate protein
function at many levels. We next examined which of the yeast
protein kinases bound hydrophobic metabolites. 103 protein
kinases representing all functional branches in yeast (HunterCell 143, 639–650, November 12, 2010 ª2010 Elsevier Inc. 641
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Table 1. Summary of Identified Small Metabolites Associated with Ergosterol Biosynthetic Proteins
Ergosterol
5,7,24(28)-
Ergostatrienol Lanosterol
4,4-Dimethyl-
Zymosterol
5a-Cholesta-8,
24-Dien-3-One Episterol
(S)-2,3-
Epoxylsqualene Pentaporphyrin
RT (min) 10.84 13.47 11.06 11.03 11.89 10.99 9.95 9.40
Mass (amu) 379.337 379.337 409.384 395.368 383.328 381.353 425.379 311.100
Element composition C28H43* C28H43* C30H49* C29H47* C27H43O C28H45* C30H49O C20H15N4
Erg1 P
Erg2 P
Erg3 P S
Erg4 P
Erg5 S
Erg6
Erg7 P S
Erg9
Erg11 S
Erg24 P
Erg25 S
Erg26 P
Erg27
Hmg1
Idi1
Mvd1 S
Erg enzymes not bound to any known intermediates or pentaporphyrin: Erg 8, Erg10, Erg12, Erg13, Erg20. Gray denotes a small metabolite-protein
association identified in this study. ‘‘P’’ and ‘‘S’’ indicate known product and substrate, respectively. Bound proteins for ergosterol and pentaporphyrin
had an enrichment greater than 3-fold and 1000-fold, respectively, and the remainder were enriched greater than 5-fold. All bound metabolites had a t
test (two-tailed unequal variance in relative to the negative control) p value less than 0.05; for ergosterol and pentaporphyrin p values of less than 0.01
and 1E10 was used. Asterisks indicate a dehydrated form of the expected formula.and Plowman, 1997) (Figure 3A) were purified and analyzed as
described above (Figure S3A). Two biological replicates were
performed for all 103 kinases, with at least three technical repli-
cates per biological replicate. A total of 95 metabolite peaks
(background and specific peaks) were identified in both experi-
ments, and these peaks were highly correlated in both retention
time and exact mass from the two batches (R2 = 0.78)
(Figure S3B). Using a stringent threshold, a total of 10 differentFigure 2. Identification of Small Metabolites Associated with Ergoster
(A) An overview of ergosterol biosynthesis pathway. Substrates and products of
fication) are in blue, whereas protein enzymes are in black (included in this study)
labeled with Q for inhibitory effects. Interactions discovered in this study are ind
(B) LC plots of the small metabolites extracted from a protein (Erg6, red), the nega
peak intensity (BPI,%) is plotted with retention time (in minutes) of corresponding
a good indicator of the intensity of single molecular masses. The 100% BPI in cou
method using two passes of window size of three scans.
(C) Combined averagemass spectra of the 10.80–11.20min region in (B) (indicated
indicated along with their chemical identities. The x axis is the peak mass (amu);
(D) Summary of the average peak intensity of two small metabolites listed in Table
indicates statistical significance (two-tailed t test, p < 0.01) in comparison with th
(E) An LC plot showing detection of pentaporphyrin I (311.100 amu at 9.40 min) fr
shows the LC of pure pentaporphyrin I.
(F) Combined mass spectra of the LC peak region in (E). Color labels are as in (E).
spectrum of pure pentaporphyrin.
(G) In vitro binding curves of pentaporphyrin and Erg proteins. Each binding cu
(specific) or a straight line (nonspecific). Binding constants Kd, Bmax, and curve-fi
is also indicated. Error bars = SD; n = 2.
See also Figure S2peaks were found to be associated with 21 protein kinases,
but not with negative (Y258) or methanol-solvent controls (Table
S2 and Figures S3C and S3E) or with many other abundant yeast
proteins (Figure S3D). The specific peaks fell into two classes.
One major class (11 of 14 analyzed) yielded reproducible peak
intensity signals (R2 > 0.9), whereas another set (3 of 14)
exhibited less correlation of peak intensities (R2 < 0.75). It is likely
that the compounds bound to the highly correlated peaksol Biosynthetic Proteins
the yeast ergosterol biosynthetic pathway (retrieved from MetaCyc with modi-
or gray (not included in this study). Known interactions are linked by a red curve
icated by green arrows from a metabolite to a binding protein.
tive control (Y258, purple), and themethanol solvent (green), respectively. Base
mass spectra (shifted by 1% for clarity). Note that BPI peaks are composite, not
nts is indicated on the graph. All traces were smoothed by the Savitzky-Golay
by a blue block arrow). Themasses of three Erg5-bound small metabolites are
the y axis is the peak intensity (%).
1 extracted from each of the 21 ergosterol biosynthetic proteins (n = 5). Asterisk
e negative control Y258. Error bars = SEM.
om Mvd1 (red), but not from Y258 (purple) or methanol samples (green). Indent
The x axis is shifted by 0.05 amu for clarity. The indent profile shows the mass
rve was subject to fitting comparison (p < 0.01) to a saturable binding curve
tting R2 are indicated (in mM) on each graph. Stoichiometry (metabolite:protein)
Cell 143, 639–650, November 12, 2010 ª2010 Elsevier Inc. 643
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Figure 3. S. cerevisiae Protein Kinase-Small Metabolite Interaction
(A) A total of 103 of 129 kinases were analyzed in this study. Kinases not tested are indicated in gray. The 21 kinases that bound small metabolites are in red.
(B) An LC plot of the small metabolites extracted from a kinase (Kin4, red), the negative control (Y258, purple), and the methanol (green). The focused retention
time region (in minutes, zoomed in 43) is indicated above the trace. Graph labels are as in Figure 2B.
(C) Combined average mass spectra of the 10.9–11.1 min region in (B). Graph label is as in Figure 2C (n = 3 for Kin4; n = 9 for Y258 and methanol). The peak
corresponding to ergosterol is marked by an asterisk.
(D) An example showing identification of a bound metabolite as ergosterol. The mass spectra of pure ergosterol, pure ergocalciferol, and one of the small metab-
olites extracted from protein kinase Ypk1 are shown on the right and their respective UPLC on the left. The elemental composition is indicated along with respec-
tive mass peaks. Graph label is as in (B) and (C).
See also Figure S3 and Table S2.represent strong steady-state interactions, and those with
differing levels of interacting metabolites interact transiently
and/or weakly (Morozov et al., 2003).
An example of specific binding is shown in Figures 3B and 3C
for Kin4, a protein kinase regulating mitotic exit (Caydasi and
Pereira, 2009). Themethanol extract fromKin4 contained a singly
charged ion of 379.337 amu at retention time 10.98min. Analysis
of standards revealed that this compound is ergosterol (dehy-
drated state) rather than ergocalciferol, a compound of identical
molecular mass (Figure 3D).
The 10 specific binding metabolites represent different lipids
and sterols; however, one kinase, Ste20, was found to bind pen-
taporphyrin, albeit at reduced levels relative to the ergosterol644 Cell 143, 639–650, November 12, 2010 ª2010 Elsevier Inc.enzymes, raising the possibility that Ste20 is associated with
this molecule. The compound identified most often among
different kinases was ergosterol, which was associated with
15 different protein kinases. None of these proteins was previ-
ously known to bind ergosterol, and, except for Yck2, none
were known to be membrane-associated. KEGG pathways
analysis reveals an enrichment of ergosterol-bound kinases in
metabolism of inositol phosphate, starch and sucrose, nicotinate
and nicotinamide, and sphingoglycolipids (Table S3). The
different ergosterol-binding kinases belong to different families
of protein kinases (Figure 3A), suggesting a potential regulatory
role of ergosterol in the regulation of many types of protein
kinases and many different aspects of yeast biology.
A B
D
C
Figure 4. Detailed Analysis of Several Kinase-Small Metabolite Interactions
(A) In vitro binding analysis of ergosterol and several protein kinases. The curve-fitting was done in GraphPad Prism 5. Error bars = SEM; n = 3. Statistical compar-
ison of curve fitting between a straight line for nonspecific binding (null) versus one-site specific binding was used to determine specific binding pattern (p < 0.05).
The R2 (unweighted) was 0.918, 0.908, and 0.933 for Hal5, Rck2, and Ypk1, respectively. The ergosterol-binding characteristics of their protein kinases are listed
below.
(B) Protein kinase activity of Ypk1 is stimulated by the addition of ergosterol. Ypk1 protein was purified from wild-type (BY4741) cells grown in the presence or
absence of 2 mM ergosterol during galactose induction of protein expression or from ergosterol-deficient yeast (erg4D). Equal amounts of purified protein were
tested in each assay. The relative activity was determined using a Sgk1-specific kinase assay. Error bars = SEM; n = 4.
(C) Levels of Ssk22 and Ypk1 in yeast. (a) Ssk22 and Ypk1 were purified from equal amounts of wild-type (BY4741) and ergosterol-lacking mutant (erg4D) cells
with or without 0.4 mM ergosterol. In three independent experiments, Ssk22 cannot be detected in erg4D. (b) Immunoblot of Ssk22 and Ypk1 from yeast cell
lysates for 7 hr after galactose induction. Proteins were probed with rabbit IgG (1:10,000 dilution of 10 mg/ml stock). Equal amounts of protein were loaded;
erg4D strains produce less protein, as indicated by relative abundance listed below (percentage of wild-type).
(D) Cell growth (absorption at 600 nm) is affected by the ergosterol-repressing drug fluconazole in mutants of ergosterol-binding protein kinases. Error bars =
SEM; n = 8. Dotted lines and gray legends are mutants of protein kinases that did not bind ergosterol in this study.
See also Figure S4.Ergosterol-Protein Kinase Interactions Have Binding
Affinities and Stoichiometries in Ranges Expected
for Physiological Relevance
To determine whether the binding coefficients observed
are likely to be physiologically relevant, the stoichiometry and
affinity of the ergosterol-protein kinase association was
determined for three kinases, Ypk1, Hal5, and Rck2, along
with three nonbinding controls, Atg1, Psk2, and denatured
Ypk1, using an in vitro binding assay that we developed
(Figure 4A). For a fixed amount of the ergosterol-bound protein
kinases, ergosterol binding exhibited a saturable curve over an
increasing concentration of free ergosterol, indicating specific
binding. In contrast, the binding curve was close to linear for
the same amount of denatured protein or control proteins(Figure S4), indicating nonspecific adsorption. The Kd for
each ergosterol-binding kinase was between 4.7 and 17.9 mM
(Figure 4A), figures significantly lower than the endogenous
concentration of 4.8 mM for ergosterol in yeast, assuming
a uniform distribution throughout the cell (Ejsing et al., 2009).
Although neither the kinase nor ergosterol is likely to be uniform
in its cellular distribution, the 4.7–17.9 mM binding constant
found for Ypk1 and the other kinases is well within a plausible
range for biological relevance. The binding ratio of ergosterol to
protein was found to be close to 1 (0.98–1.1, 95% confidence
interval) for each protein kinase, suggesting that one small
metabolite binds to one protein (Figure 4A). This ratio is consis-
tent with an in vivo biological role for ergosterol in regulating
kinase activity.Cell 143, 639–650, November 12, 2010 ª2010 Elsevier Inc. 645
Ergosterol Regulates the Activity of a Highly Conserved
Kinase, Ypk1, and Influences the Ssk22 Levels
To determine whether ergosterol binding is important for kinase
function, we tested the effect of ergosterol on Ypk1 activity using
in vitro kinase assays (Figure 4B). Ypk1 is a yeast homolog of the
mammalian SGK/AKT protein kinases, which are involved in
many important cellular processes and human disease (Brazil
and Hemmings, 2001); yeast Ypk1 has been implicated in
receptor-mediated endocytosis and sphingolipid-mediated
signaling (Jacquier and Schneiter, 2010). Ypk1 was purified
from wild-type cells grown in the absence and presence of
0.4 mM ergosterol and was tested for stimulation of in vitro
kinase activity in the presence of increasing concentrations of
ergosterol. Ypk1 activity from cells grown in the absence of
ergosterol is significantly (and reproducibly) elevated in the
presence of increasing amounts of ergosterol (Figure 4B). Ypk1
activity was even higher when cells were grown in the presence
of ergosterol and could be stimulated to a similar extent.
Because Ypk1 was isolated from wild-type cells that contain
ergosterol, it might already contain bound ergosterol. We
therefore purified Ypk1 protein from an erg4D strain that lacks
ergosterol (Parks and Casey, 1995). Ypk1 protein levels were
similar to preparations from wild-type cells (Figure 4Ca);
however, Ypk1 activity was very low in erg4D strains (at least
5-fold lower) relative to wild-type cells and could not be stimu-
lated (Figure 4B). These results demonstrate that ergosterol
stimulates Ypk1 kinase activity. Because Ypk1 isolated from
erg4D strains was low and could not be stimulated, it is likely
that some ergosterol must be present during Ypk1 synthesis
and activation. Overall, these results demonstrate that ergosterol
is critical for Ypk1 activity.
We also attempted to analyze the activity of Ssk22 (a kinase
involved in osmosensing [Posas et al., 1996]) in wild-type and
erg4D cells. In multiple independent experiments, we found
that we could not purify Ssk22 from erg4D strains lacking ergos-
terol (Figure 4Ca). Addition of exogenous ergosterol to the
medium restored Ssk22 levels in the mutant strain. To explore
this further, Ssk22 levels were examined for up to 7 hr after
expression was induced from a GAL promoter. As shown in
Figure 4Cb, copious amounts of Ssk22 protein are detected in
wild-type cells, but levels are substantially reduced (6- to 20-
fold) in erg4D cells (Figure 4Cb). Although the levels of Ssk22
were too low to measure kinase activity, our results demonstrate
that ergosterol is important for maintaining Ssk22 protein levels
in wild-type yeast.
Growth of Strains Deleted for Ypk1 and Other
Ergosterol-Binding Proteins Is Affected
by Ergosterol Inhibitors
We next determined whether ergosterol levels are important for
the growth of yeast strains lacking ergosterol-binding kinases.
Yeast strains lacking Ypk1were shown previously to be sensitive
to nystatin and fluconazole, two inhibitors of ergosterol biosyn-
thesis (Gupta et al., 2003; Hillenmeyer et al., 2008). Six strains
deleted for different ergosterol-binding kinases, as well as four
strains deleted for kinases not found to bind ergosterol, were
grown in the presence of different concentrations of fluconazole,
and cell density was determined. As shown in Figure 4D, growth646 Cell 143, 639–650, November 12, 2010 ª2010 Elsevier Inc.of ypk1D cells was inhibited by fluconazole, whereas ssk22D
were resistant to fluconazole. Similarly, ypk1D cells were sensi-
tive to nystatin (data not shown). The mutants of four other
ergosterol-binding protein kinases behaved similarly to the
wild-type cells and strains lacking nonergosterol binding
kinases. These results indicate that genetic interactions are
evident between ergosterol-bound kinases and the ergosterol
pathway.
An Integrated Global Small Metabolite-Protein Network
To better view how our results might be connected with other
regulatory interactions, we next integrated the small metabo-
lite-protein binding results with protein-protein interaction
data, genetic interaction data, and metabolite networks con-
structed by others. Our results suggest a highly connected
network of interactions in which the small metabolites add an
extra dimension of regulatory information. We found extensive
interactions between the ergosterol-bound kinases, the ergos-
terol biosynthesis proteins, and a wide variety of other cellular
components. Simplification of the network to only those inter-
actions that directly interact with the Erg pathway and ergos-
terol-bound kinases reveals a bipartite pattern (Figure 5A). Of
interest, the kinases are connected to their interacting partners,
whereas ergosterol pathway proteins interact through genetic
and phenotypic interactions. We suggest that Erg pathway
components often operate in the same pathways as the
affected kinases and/or small metabolite products of the
pathway affect kinase regulators and/or substrates. Overall,
our results demonstrate close functional connections between
ergosterol biosynthetic pathway components and ergosterol-
bound kinases.
Within the overall interaction network is a variety of interesting
interactions. For example, Erg20, an essential enzyme for both
isoprenoid and ergosterol (Daum et al., 1998), is indirectly phos-
phorylated by ergosterol-bound protein kinases Sat4 via Tpk1,
whereas five other enzymes, Erg1, Erg4, Erg6, Erg7, and
Erg26, are transcriptionally regulated by five proteins (in the
middle circle, Figure 5A). In addition, 13 of 21 enzymes (62%)
in the ergosterol pathway and three ergosterol-binding kinases
(Ypk1, Yak1, andMck1) have physical interactions with the ubiq-
uitin Ubi4. This figure is statistically significant (p value = 1.5e5
by Fisher’s exact test), as only 18% of all yeast proteins have
physical interaction with Ubi4 (Figure 5A, bottom). Perhaps
many components involved in ergosterol biosynthesis are
modified and/or degraded by the Ubi4-mediated ubiquitination
pathway.
We next conducted gene function enrichment analyses for
the 137 yeast genes known to interact physically, genetically,
or phenotypically with both 1 of the 21 ergosterol biosynthetic
proteins and 1 of the 15 ergosterol-bound protein kinases
(Figure 5A, top). Several categories of cell division and growth
are particularly overrepresented, such as cell cycle, stress
responses, transcription, and general metabolism of lipids, vita-
mins, and carbohydrates (Table S3 for KEGG pathway and
Figure 5B for gene ontology). These results further suggest that
ergosterol can act through modulation of protein kinase activa-
tion as a general regulator in coordinating various cellular biolog-
ical processes.
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Figure 5. Integrative InteractomesofProteins andSmallMetabolites
(A) (Top) A protein-protein interaction network showing intermediate proteins
(green circles) that link ergosterol-binding protein kinases (purple diamonds)
from this study and ergosterol biosynthetic enzymes through known physical
or genetic interactions or common phenotypes (red hexagons). The edge
colors denote interaction types: green for physical, blue for genetic and pheno-
typic, purple for phosphorylation, red for metabolic, and olive for transcription
factor binding. (Middle) A subnetwork showing a group of intermediate
proteins phosphorylated by ergosterol-bound protein kinases and regulating
ergosterol enzymes through transcription and phosphorylation. (Bottom) A
subnetwork showing only ubiquitin (Ubi4)-interacting intermediate proteins
and ergosterol enzymes.
(B) Gene ontology (GO) enrichment analysis of the 137 intermediate proteins in
(A, top). p < 0.01 for hypergeometric test against GOSlim_Yeast.
See also Table S3.DISCUSSION
A Large Number of Metabolite-Protein Interactions
Exist in Eukaryotes
Inside a cell, most proteins presumably encounter various small
metabolites, which are in vast numerical excess, as they consti-
tute 5%–8% of total cell weight (Alberts, 2002) and possess
a small molecular weight (<1000 Da). Although these encounters
may not always have functional consequences, it is likely that
many of them will be important in modulation of protein/enzyme
activity. Our study presents a systematic analysis of in vivo
metabolite-protein interactions and has revealed many such
interactions in a eukaryotic cell. Approximately 70% of ergos-
terol biosynthetic proteins and 20% of protein kinases were
found to bind hydrophobic molecules. If a similar percentage
exists for the entire proteome as found for protein kinases,
then > 1200 soluble yeast proteins would bind hydrophobic
molecules. The analysis of hydrophilic small metabolites is likely
to increase the fraction of metabolite-binding proteins even
further. Thus, a substantial number of eukaryotic proteins are
likely to bind metabolites.
One important advantage of an unbiased and systematic
analysis of in vivo protein-metabolite interactions is that many
unexpected interactions are revealed. These include interactions
of protein kinases with sterols and the binding of ergosterol
biosynthetic proteins to different ergosterol-related metabolites
and pentaporphyrin, a heme-related compound that presumably
binds noncovalently to proteins. In many cases, the results can
explain previous unexplained observations. For example, yeast
strains that are defective in heme biosynthesis fail to grow in
the absence of ergosterol (Parks and Casey, 1995). Likewise,
the finding that erg7mutants fail to grow in the absence of ergos-
terol may be due to our observation that lanosterol binds and
likely regulates many key steps in the Erg pathway. Finally, the
observation that ypk1 mutants fail to grow in the presence of
ergosterol inhibitors is consistent with a role for ergosterol in
Ypk1 pathway or related pathway function. Thus, the advantage
of an unbiased screen revealsmany new interactions that appear
to be functional in vivo and provides potential insights into
previously unexplained mutant phenotypes.
An Assay for In Vivo Protein-Small Metabolite
Interactions
Investigation of protein-small metabolite interactions is difficult
for two reasons. First, sufficient quantities of proteins are
required for detection, and many proteins can be difficult to
purify. Second, small metabolites vary in chemical properties,
which prohibits a universal detection method for untargeted
profiling. We overcame these challenges by using an epitope-
tagged protein expression system for systematic analysis of
large numbers of proteins in yeast (Gelperin et al., 2005) and
sensitive MS to detect trace amounts of small metabolites at
picomole scales. We further customized our MS approach to
target nonpolar hydrophobic small metabolites because of the
concern of losing hydrophilic metabolites during protein purifica-
tion and aqueous washes (Morozov et al., 2003). The assay that
we developed will not detect nonvolatile compounds and may
miss many phospholipids (albeit, see Carrier et al., 2000) andCell 143, 639–650, November 12, 2010 ª2010 Elsevier Inc. 647
perhaps other compounds as well. Nonetheless, it is capable of
detecting many diverse compounds (Table 1 and Table S2) and
yields not only reproducible and simple mass spectra amenable
for further interpretation (Figure 2 and Figure 3), but also mean-
ingful results that could be validated using other assays
(Figure 4). With modification, this method may also be used for
profiling protein-bound hydrophilic metabolites.
Our method differs significantly from several studies (Maynard
et al., 2009; Morozov et al., 2003; Tagore et al., 2008) in several
important aspects: (1) we detect in vivo bound small metabolites,
which is analogous to coimmunoprecipitation, a gold standard
method for detecting in vivo protein-protein interactions, (2) the
metabolomic composition exposed to each protein of study is
at its in vivo physiological state, thus avoiding bias due to over-
loading and/or disproportional composition of small molecules
that can occur in in vitro studies, and (3) the procedure we
have established is highly scalable and can be used to analyze
large number of proteins.
Our current method cannot distinguish between physical and
indirect association of protein and small metabolites, as the
metabolites that we identify may purify with associated
proteins. Thus, the results are analogous to those for protein-
protein interaction studies that use affinity purification or two
hybrid methods. Because the purified protein preparations
typically have a single overproduced peptide, it is likely that
most interactions are direct, but indirect interactions are
possible. In some cases, the interaction might be suggestive
of a membrane association; for the cases of ergosterol-bound
protein kinases, none have transmembrane domains, and only
one, Yck2, has been shown to be membrane associated
through palmitoylation (Babu et al., 2004). Other limitations of
our assay are: (1) Transient interactions, as might be expected
in interactions with substrates and products, may be difficult to
observe. Those that are detected may prove to be important
limiting steps that control biochemical flux through pathways;
(2) Interactions not normally present within the cell might be
detected because the proteins are overproduced; (3) False
negatives and false positives are difficult to assess. False nega-
tives may be transient interactions, have high off rates in
aqueous phase, or require particular interaction conditions
(e.g., protein modifications or interacting partners); apparent
false positives may be bona fide events that occur under condi-
tions that have not been assessed previously or due to nonspe-
cific interactions.
The metabolite-protein interactions are likely to be specific for
several reasons. First, only a limited number of metabolites were
found to be bound to any protein, and distinct metabolites are
bound to a particular protein and even between closely related
proteins. In fact, the majority of yeast proteins do not bind ergos-
terol or other metabolites, even though most are just as abun-
dant in our preparations as the metabolite binding proteins
(Figure S3D). Second, the stoichiometry of the protein-small
metabolite interaction is usually on the order of 1:1 (or 1:2 for
Erg27), suggestive of specific interaction. Third, for most of the
interactions, the signal intensities are highly reproducible
between experiments. These results are consistent with specific
interactions rather than nonspecific adsorption to protein
surfaces. Thus, although some of the interactions that we detect648 Cell 143, 639–650, November 12, 2010 ª2010 Elsevier Inc.may be nonspecific, our data indicate that many of them are
specific.
Small Metabolites as General Regulators
of Cellular Processes
As demonstrated in this study, ergosterol, an important building
material for new cell membranes, regulates the activity of Ypk1
(Schmelzle et al., 2002) and the levels of Ssk22. Ypk1 is impor-
tant for stress response, cell wall integrity, lipid uptake, and
budding (Jacquier and Schneiter, 2010), and Ssk22 is involved
in the Hog1-mediated osmosensory pathway (Posas et al.,
1996). Because even low ergosterol concentrations can stimu-
late Ypk1 activity, it is possible that Ypk1 is a biomass sensor
for ergosterol levels and helps to coordinate cell wall synthesis
and budding. The positions of both ergosterol and Ypk1 in the
integrated network (Figure 5) are consistent with key roles in
coordinating these processes along with cell-cycle control and
other related biological processes (Table S3). Furthermore, the
role of ergosterol as a coordinator of manymolecular and cellular
processes has general similarities to other key molecular regula-
tors such as cAMP and phospholipid derivatives (Alberts, 2002).
Because ergosterol is a critical component of cell membranes, it
is ideally suited to coordinate membrane synthesis with related
biological processes that depend upon membrane and cell
integrity such as the stress response, endocytosis, budding,
and cell division. The regulation by ergosterol may differ from
classical signaling regulators in terms of magnitude and selec-
tivity because, as a structural component of membranes, ergos-
terol serves more diverse general roles than small molecules
made specifically for signaling. As such, ergosterol is well situ-
ated for simultaneously monitoring cell integrity, intracellular
processes, and environmental interactions. In addition to
possible roles as a structural component and signalingmolecule,
ergosterol might also serve as a facilitator of protein folding, as
cells grown in the absence of ergosterol have low Ypk1 kinase
activity and low levels of Ssk22. Perhaps ergosterol is important
for the proper folding of these enzymes and homeostasis for
Ssk22.
Small Metabolites and Human Disease
The interplay of metabolites and proteins may have profound
importance in human health. Strong associations between urine
metabolites and human diseases have been documented (e.g.,
Nicholson et al., 2008). Thus, the knowledge gained from this
study may pave the way, not only to more fully understand the
molecular basis of disease, but to potentially modulate specific
biological pathways by manipulating the metabolite concentra-
tion through nutrient uptake or intervention. Consistent with the
latter possibility, many key enzymatic steps are controlled by
pharmaceuticals that are analogs of cellular metabolites; these
could be used to modulate pathways regulated by metabolite
interactions.
EXPERIMENTAL PROCEDURES
Yeast Strains and Media
Yeast MORF strains expressing tagged proteins were grown and processed
as described previously (Gelperin et al., 2005). Yeast knockout strains were
from Yeast Genome Deletion Project. Y258 is MATa pep4-3, his4-580,
ura3-53, leu2-3,112. The Y258 strain used as negative control in this study
was integrated with a URA3 gene from pRS426 vector. For yeast transforma-
tion, MORF plasmids were rescued from yeast MORF strains and then intro-
duced into the yeast using standard methods (Gietz and Woods, 2002).
Standard YPAD or SC-URA media supplemented with glucose, raffinose, or
galactose were used. For ergosterol treatments, a suspension at 0.05 g/ml
in ethanol was added to 300 volumes of a yeast raffinose culture.
Affinity Purification and Metabolite Extraction
Frozen yeast cell pellets from 150 ml cultures were resuspended in 1 ml lysis
solution (200 mM NH4Ac, 1 3 Complete Protease Inhibitor Cocktail [Roche],
and 1 mM EGTA). One volume of Zirconia silica beads was added to facilitate
cell lysis using a FastPrep 24 machine (MP Biomedicals) and a setting of 60 s
for three times at 6.5 m/s. The lysis was repeated once with another 1 ml of
lysis solution. The combined supernatants were then incubated with 50 ml of
rabbit IgG-crosslinked M-270 epoxy Dynabeads (Invitrogen) for 2 hr at 4C.
The beads were washed once in 300 mM NH4Ac and once in 150 mM
NH4Ac; each wash lasted 5 min. To extract the protein-bound metabolites,
60 ml of pure methanol was added to the beads and incubated at RT for
10 min. The methanol extract was then immediately transferred to a Waters
max recovery glass vial and analyzed by a mass spectrometer on the same
day. The beads were then boiled in 30 ml 2 3 SDS sample buffer for 10 min,
and 15 ml of the supernatant was loaded on a 4%–15% SDS-PAGE gel for
separation and stained by ProtoBlue Safe reagent (National Diagnostics).
UPLC-Coupled APCI Mass Spectrometry
The mass spectrometry system used in this study was comprised of an
Acquity UPLC system and a Micromass Q-TOF mass spectrometer equipped
with an APCI probe (Waters Co., Milford, MA). The operating software was
MassLynx v4.1 (Waters Co., Milford, MA). For each run, 10 ml metabolite
extract was loaded on an Acquity UPLC BEH C18 column protected by
a VanGuard precolumn using a binary solvent gradient of 0%–100%methanol
in water for 10min and 100%methanol for another 10min. The collectionmass
range was 100–1500 m/z in profile scan mode to avoid missing uncommon
mass adducts. The probe and source temperatures were 500C and 130C,
respectively.
Mass Spectrometry Assay Development and Validation
Pure standards of highest available purity were prepared in methanol to 10 mM
final concentration. Five ml of the solution was loaded on the same LC system
using identical gradient settings. The results were then compared with the
mass peaks from real samples and other known compound standards for
matched retention time and monoisotopic exact mass patterns. Most identifi-
cations were performed using MarkerLynx or XCMS. For ergosterol, lano-
sterol, and pentoporphyrin, standards were also analyzed by LC-MS (Figure 2,
Figure 3, and Figure S1).
In Vitro Small Metabolite-Protein Binding Assay
Purified protein kinases (in 50 mM HEPES [pH 7.5], 150 mM NaCl, 0.1% Triton
X-100, and 30% glycerol) were either kept on ice (native) or boiled for 10 min
(denatured) before distribution in 10 ml aliquots. One ml of ergosterol stock
(in 10% DMSO) or pentaporphyrin stock (in methanol) was added from
a 2-fold dilution series. After incubation for 15 min at 25C, the mixture was
loaded to Zeba desalting microcolumn (Pierce) for 2 min. Ninety ml of methanol
was then added to the flowthrough and vortexed briefly before loading on
mass spec for quantification. A standard curve was constructed using the
loading standards diluted 1000-fold in methanol. The quantification method
was optimized with 10 mM ergosterol or pentaporphyrin on a TSQ Vantage
triple quad (Thermo) run on SRM mode. The monitored reaction transition
was 379 m/z to 239 m/z for ergosterol and 331 m/z to 282 m/z for pentapor-
phyrin, respectively.
In Vitro Kinase Activity Assay
Kinase activity assay was performed on Corning 384-well plates using Z0-lyte
Kinase Assay Kit-Ser/Thr 6 Peptide according to manual instruction (Invitro-
gen). The incubation time was 2 hr at 25C. Protein and ATP concentrations(1 mM) were determined empirically by titration according to manufacturer’s
instruction.
Data Analyses
The mass spectra were first analyzed in MarkerLynx SCN639 to generate
a table with peak intensity, peak elemental composition, and associated
proteins. Peak intensity averages and the t test (two-tailed comparison
assuming unequal variance) were calculated in Microsoft Excel. Stringent
thresholds were used (see Figure S1D for the MarkerLynx settings; thresholds
are in Figure S3C legend and Table 1). The initial cutoff value of signal-to-noise
ratio was set toR 5. For XCMS analysis (Smith et al., 2006), mass spectra were
first centroided and converted to netCDF format in MassLynx. UPLC- and
Q-TOF-specific peak calling and grouping parameters were used.
Construction of Interaction Network
All networks were visualized using Cytoscape (Shannon et al., 2003). The raw
interaction network was created by including all genes that interact with one of
the ergosterol-bound kinases and one of the proteins in the Erg pathway. The
interactions were gathered from BioGRID (Breitkreutz et al., 2008), transcrip-
tion factor binding data (Teichmann and Babu, 2004), and phosphorylome
data (Ptacek et al., 2005).
Gene Function Enrichment Analyses
The GO enrichment graph was created using the raw interaction network after
filtering phosphorylation and transcription factor binding data. The genes in
the middle layer of the resulting network were analyzed by BiNGO (Maere
et al., 2005).
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